Literature DB >> 6840839

Effect of highly purified coagulase and culture filtrate on virulence and immunity of a coagulase-negative mutant of staphylococcus aureus BB.

N Hasegawa, I Kondo, S Hoshina, K Kurosaka, H Igarashi.   

Abstract

The virulence of the coagulase-deficient mutant BB-Cgl- 1301 (50% lethal dose [LD50] for mice by the intravenous route) was compared with that of its parental strain, Staphylococcus aureus BB. The BB strain produced free coagulase of serotype I, whereas the mutant 1301 did not. Mice were infected with strain 1301, alone or in combination with a highly purified coagulase type I or type II solution, or with concentrated culture filtrates of parent strain BB or mutant strain 1301. The ratios of the LD50S of 1301 and its combinations to that of BB ranged from 34.9 to 461. Combining strain 1301 with a concentrated culture filtrate of BB (BB-CF2.5) was the most effective for enhancement of its virulence. When mice were infected with a combination of strain 1301 and BB-CF2.5, the LD50 of strain 1301 (1.72 mg of cells [wet weight]) was decreased to 0.13 mg (1.3 x 10(8) CFU). This LD50 yielded the smallest ratio, 34.9, as compared with the LD50 of BB (0.00373 mg). In contrast, when the mice subcutaneously immunized with strain 1301 and BB-CF50 were intravenously challenged by strain BB, the LD50 for the immunized mice was 17.4 times the LD50 for the unimmunized control mice (0.0429 mg as compared with 0.00246 mg), indicating that combination was the most effective for enhancement of mouse immunization with strain 1301. However, combining strain 1301 with the highly purified sample of coagulase increased neither the virulence nor the immunizing power of mutant strain 1301.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6840839      PMCID: PMC348089          DOI: 10.1128/iai.39.3.1236-1242.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  PURIFICATION AND CHARACTERIZATION OF STAPHYLOCOAGULASE.

Authors:  Z ZOLLI; C L SANCLEMENTE
Journal:  J Bacteriol       Date:  1963-09       Impact factor: 3.490

2.  DETERMINATION OF POTENTIAL PATHOGENICITY OF STAPHYLOCOCCI.

Authors:  H R ELSTON; D M FITCH
Journal:  Am J Clin Pathol       Date:  1964-10       Impact factor: 2.493

3.  Studies on staphylococal coagulase. II. Coagulase typing of staphylococci and its relation to phage typing.

Authors:  H ZEN-YOJI; T TERAYAMA; M BENOKI; S KUWAHARA
Journal:  Jpn J Microbiol       Date:  1961-07

4.  Studies on staphylococci. II. Effect of coagulase on the virulence of coagulase negative strains.

Authors:  R D EKSTEDT; W W YOTIS
Journal:  J Bacteriol       Date:  1960-10       Impact factor: 3.490

5.  Characteristics of coagulase positive and coagulase negative staphylococci in serum-soft agar.

Authors:  R A FINKELSTEIN; S E SULKIN
Journal:  J Bacteriol       Date:  1958-03       Impact factor: 3.490

6.  Significance of protein a production by staphylococci.

Authors:  A Forsgren
Journal:  Infect Immun       Date:  1970-11       Impact factor: 3.441

7.  Identification of Staphylococcus pyogenes by the phosphatase reaction.

Authors:  M BARBER; S W A KUPER
Journal:  J Pathol Bacteriol       Date:  1951-01

8.  A note on some points of calculation method of LD50 by Reed and Muench.

Authors:  M MATUMOTO
Journal:  Jpn J Exp Med       Date:  1949-09

9.  A new method for purification of staphylocoagulase by a bovine prothrombin-Sepharose column.

Authors:  H Igarashi; T Morita; S Iwanaga
Journal:  J Biochem       Date:  1979-11       Impact factor: 3.387

10.  The survival of staphylococci within human leukocytes.

Authors:  D E ROGERS; R TOMPSETT
Journal:  J Exp Med       Date:  1952-02       Impact factor: 14.307

View more
  3 in total

Review 1.  Exploring Staphylococcus aureus pathways to disease for vaccine development.

Authors:  Andrea DeDent; Hwan Keun Kim; Dominique Missiakas; Olaf Schneewind
Journal:  Semin Immunopathol       Date:  2011-12-01       Impact factor: 9.623

Review 2.  Alternative sigma factors and their roles in bacterial virulence.

Authors:  Mark J Kazmierczak; Martin Wiedmann; Kathryn J Boor
Journal:  Microbiol Mol Biol Rev       Date:  2005-12       Impact factor: 11.056

3.  Dabigatran inhibits Staphylococcus aureus coagulase activity.

Authors:  Thomas Vanassche; Jan Verhaegen; Willy E Peetermans; Marc F Hoylaerts; Peter Verhamme
Journal:  J Clin Microbiol       Date:  2010-09-01       Impact factor: 5.948

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.